The markets opened mixed with the Dow slipping 23 points to 15,348 while Nasdaq climbed 31 points to 3894 as investors monitored earnings.
On the upside
Zhone Technologies (Nasdaq: ZHNE) reversed year ago losses to post a profit for the third quarter and the company expects record results for the full year.
Align Technology (Nasdaq: ALGN) swung to a better than expected profit for the third quarter as revenue climbed and the company forecast current quarter results ahead of estimates.
Shares of ParkerVision (Nasdaq: PRKR) continued rising.
On the downside
Ariad Pharmaceuticals (Nasdaq: ARIA) terminated its Phase 3 EPIC trial of its chronic myeloid leukemia drug Iclusig.
Bank of America/Merrill Lynch downgraded Advanced Micro Devices (NYSE: AMD) from a Buy rating to a Neutral rating.
TheStreet wrote that the Lambert-Eaton Myasthenic Syndrome treatment that Catalyst Pharmaceuticals (Nasdaq: CPRX) is developing is already available for free to patients.
In the broad market, advancing issues outpaced decliners by a margin of nearly 5 to 2 on the NYSE and by nearly 2 to 1 on Nasdaq. The broader S&P 500 gained 5 points to 1738.